Cardiology
Latest news
974 articles · 20 / page
Survival Proportional Odds Outperforms Cox Regression in High-Heterogeneity Heart Failure Trials: Insights from DAPA-HF and DELIVER
A critical reanalysis of the DAPA-HF and DELIVER trials reveals that the survival proportional odds model provides greater statistical power and more robust treatment effect estimates than traditional Cox regression in heart failure populat
Plasma Proteomics Unveils VEGFR1 as a High-Precision Prognostic Biomarker in Cardiogenic Shock
A large-scale proteomic analysis identifies VEGFR1 as a significant, independent predictor of 180-day mortality in patients with cardiogenic shock, offering incremental prognostic value beyond traditional markers like serum lactate and SAPS
Minima Stent System Proves Safe and Effective for Vascular Stenosis in Infants: Results of the Multicenter Pivotal Trial
A multicenter trial confirms the Minima Stent’s efficacy in treating pulmonary artery stenosis and aortic coarctation in infants. With a 97.6% success rate and growth-accommodating design, it addresses a critical unmet need in pediatric int
TAVR vs. SAVR in Younger Low-Risk Patients: 3-Year NOTION-2 Insights Highlight Bicuspid Challenges
Three-year results from the NOTION-2 trial show comparable clinical outcomes between TAVR and SAVR in younger, low-risk patients. However, higher event rates in the bicuspid subgroup suggest a need for caution and individualized procedural
Precision Medicine in Atrial Fibrillation: Biomarker-Based ABC-AF Risk Scores Fail to Outperform Standard Care
A large-scale registry-based RCT reveals that tailoring atrial fibrillation treatment using the biomarker-driven ABC-AF risk score does not significantly reduce stroke or death compared to current standard guideline-based care, highlighting
Routine Cerebral Embolic Protection Fails to Mitigate Stroke or Cognitive Decline in TAVI: Results from the BHF PROTECT-TAVI Trial
The landmark BHF PROTECT-TAVI trial reveals that cerebral embolic protection (CEP) does not reduce periprocedural stroke or cognitive impairment following TAVI. This large-scale study challenges the routine use of embolic filters, suggestin
Aspirin vs. Clopidogrel Beyond 30 Days Post-PCI: Equivalent Outcomes Regardless of Oral Anticoagulation Status
A subgroup analysis of the STOPDAPT-3 trial reveals that aspirin and clopidogrel offer similar cardiovascular protection and bleeding safety between 1 month and 1 year post-PCI, regardless of whether patients are also receiving oral anticoa
The Achilles’ Heel of Left Main Bifurcation: Circumflex Ostium Remains the Primary Site of Restenosis Regardless of Stenting Strategy
A subanalysis of the EBC MAIN trial reveals that the circumflex ostium is the most frequent site of restenosis following left main bifurcation stenting, occurring in 71% of patients requiring revascularization, regardless of whether a singl
Abluminus DES+ Fails to Achieve Non-Inferiority Against XIENCE EES in Patients with Diabetes: Results from the ABILITY Diabetes Global Trial
The ABILITY Diabetes Global trial demonstrates that the Abluminus DES+ sirolimus-eluting stent failed to meet non-inferiority compared to the XIENCE everolimus-eluting stent in patients with diabetes, showing significantly higher rates of t
Mechanical Thrombectomy Superior to Anticoagulation Alone for Rapid Right Ventricular Recovery in Intermediate-High Risk Pulmonary Embolism: Results from the STORM-PE Trial
The STORM-PE trial, the first randomized controlled trial of its kind, demonstrates that computer-assisted vacuum thrombectomy (CAVT) significantly improves right ventricular recovery and reduces clot burden compared to anticoagulation alon
Prediabetes and Silent Cardiac Injury: A High-Risk Synergy for Heart Failure in Hypertensive Patients
A post hoc analysis of the SPRINT trial reveals that the coexistence of prediabetes and subclinical myocardial injury or stress significantly escalates heart failure risk in hypertensive adults, suggesting a need for integrated glycemic and
Vanishing Act: Novel Biodegradable PFO Closure Device Matches Nitinol Efficacy in Landmark Randomized Trial
A multicenter randomized trial confirms that a novel biodegradable PFO closure device is noninferior to nitinol devices, achieving high closure rates and disappearing from echocardiography within two years, potentially reducing long-term fo
Semaglutide Delivers Consistent Functional Gains in Peripheral Artery Disease Regardless of Sex: Evidence from the STRIDE Trial
A post hoc analysis of the STRIDE trial reveals that once-weekly semaglutide 1.0 mg significantly improves walking distance and quality of life in both men and women with type 2 diabetes and peripheral artery disease, despite notable differ
Is Indefinite Heart Failure Therapy Necessary After AF Rhythm Control? Insights from the WITHDRAW-AF Trial
The WITHDRAW-AF trial suggests that heart failure therapy can be safely withdrawn in patients with atrial fibrillation-mediated cardiomyopathy who achieve rhythm control and ejection fraction normalization, showing no significant decline in
Targeted Education Enhances Rhythm Control Adherence in Atrial Fibrillation but Faces Limits in Stroke Prevention: Insights from STEEER-AF
The STEEER-AF cluster-randomized trial reveals that structured professional education significantly boosts adherence to complex rhythm control guidelines in atrial fibrillation, though it shows no significant impact on stroke prevention whe
Colchicine May Curb the Expansion of Pro-Inflammatory Clonal Hematopoiesis: Insights From the LoDoCo2 Substudy
A substudy of the LoDoCo2 trial suggests that low-dose colchicine may attenuate the expansion of specific clonal hematopoiesis driver mutations, particularly TET2, offering a potential mechanism for reducing cardiovascular risk by slowing t
Ketone Esters in HFpEF: Metabolic Reprogramming and Hemodynamic Gains Fail to Translate into Improved Exercise Capacity
The KETO-HFpEF trial demonstrates that while acute ketone ester supplementation effectively induces ketosis and improves resting hemodynamics, it fails to improve peak oxygen consumption or exercise endurance in patients with heart failure
Mavacamten Redefines Long-Term Outcomes in Obstructive Hypertrophic Cardiomyopathy: 128-Week Results From the VALOR-HCM Trial
The 128-week follow-up of the VALOR-HCM trial demonstrates that mavacamten provides sustained relief from LVOT obstruction, promotes favorable cardiac remodeling, and significantly reduces the need for invasive septal reduction therapy in p
Complete Revascularization Benefits Older MI Patients Regardless of Renal Function: Insights from the FIRE Trial
A sub-analysis of the FIRE trial demonstrates that physiology-guided complete revascularization significantly reduces major adverse cardiovascular events in patients aged 75 and older, irrespective of baseline kidney function, without incre
Validating the 0.80 FFR Threshold: Long-Term Outcomes from the NOTION-3 Trial in TAVR Patients
The NOTION-3 trial demonstrates that FFR-guided revascularization significantly reduces cardiovascular risks in TAVR patients with coronary artery disease, validating the 0.80 threshold for clinical decision-making.
Browse by specialty
Open language-specific specialty feeds and department pages.